Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial

Article English OPEN
Jensen,Gitte; Lenninger,Miki; Ero,Michael P.; Benson,Kathleen;
(2016)
  • Publisher: Dove Medical Press
  • Journal: Integrated Blood Pressure Control, volume 9, pages 95-104 (issn: 1178-7104, eissn: 1178-7104)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.2147/IBPC.S99553, pmc: PMC5066864
  • Subject: subtilisin NAT | plasma Renin activity. | von Willebrand factor | plasma renin activity | diastolic blood pressure | Clinical Trial Report | Internal medicine | Integrated Blood Pressure Control | RC31-1245 | systolic blood pressure

Gitte S Jensen,1 Miki Lenninger,1 Michael P Ero,2 Kathleen F Benson,1 1NIS Labs, Klamath Falls, OR, 2Machaon Diagnostics, Inc., Oakland, CA, USA Objective: The objective of this study is to evaluate the effects of consumption of nattokinase on hypertension in a North Am... View more
  • References (45)
    45 references, page 1 of 5

    1. Kim MJ, Lim NK, Choi SJ, Park HY. Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. Hypertens Res. 2015;38(11):783-789.

    2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-1992.

    3. Mancia G, Fagard R, Narkiewicz K, et al; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3-16.

    4. U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007;147:783.

    5. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(3):192-204.

    6. Krause T, Lovibond K, Caulefild M, McCormack T, Williams B; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.

    7. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379(9819):905-914.

    8. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scienticfi statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52(1):1-9.

    9. Yoon S, Ostchega Y, Louis T. Recent Trends in the Prevalence of High Blood Pressure and Its Treatment and Control, 1999-2008. Hyattsville, MD: National Center for Health Statistics; 2010. [NCHS data brief, no 48].

    10. Fryar CD, Hirsch R, Eberhardt MS, et al. Hypertension, High Serum Total Cholesterol, and Diabetes: Racial and Ethnic Prevalence Differences in U.S. Adults, 1999-2006. Hyattsville, MD: National Center for Health Statistics; 2010. [NCHS data brief, no 36].

  • Metrics
Share - Bookmark